Semax
NOT FDA APPROVEDCognitive / neuroprotective peptide
Also known as: ACTH(4-10) analog
Not FDA approved. Registered as a medicine in Russia; sold elsewhere as a research chemical.
Early evidence, mostly unproven in humans
- Regulatory standing. Sold as a research chemical, not approved
- Limited human data. Some human data exists, not conclusive
- No registered human trials. Nothing registered on ClinicalTrials.gov
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven mostly in Russian clinical settings (stroke, cognition), where it is a registered drug. Western, independently replicated trials are limited, so by FDA-grade standards the cognitive benefits are suggestive, not firmly established.
What it is
A synthetic ACTH fragment analog proposed to modulate BDNF and neuroprotective pathways.
What the research says
Russian clinical studies support use; independent Western replication is limited.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Semax in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Respiratory acoustic thoracic imaging (RATHI): assessing deterministic interpolation techniques.
Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog.
Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia.
Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Semax is the intervention being tested.
No interventional studies for Semax are registered on ClinicalTrials.gov. That is not proof it is unsafe or useless, but it means the human evidence here does not come from registered clinical trials, the exact gap the marketing tends to hide.
FDA recalls & enforcement
Semax has no FDA recall or drug record at all — because it is not an FDA-regulated drug. That absence is not a safety signal. It means this compound is sold outside the system that inspects, tracks and recalls unsafe products in the first place.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- Limited independent safety data outside its country of registration.
- Gray-market purity varies.
Doses reported in studies & protocols
Intranasal protocols vary. No FDA-established dose. This is not a recommendation.
Purity reality
A COA is the only way to confirm content.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.